Trial begins of needle-free Covid vaccine targeting new variants

A trial has begun of a new needle-free Covid-19 vaccine to protect against future variants of the virus.

The vaccine, administered through a jet of air, has been developed by Prof Jonathan Heeney of Cambridge University and chief executive of DIOSynVax.

Participants, aged between 18 and 50 years old, will take part at the NIHR Southampton Clinical Research Facility.

Prof Heeney said: “As new variants emerge and immunity begins to wane we need newer technologies.”